Supernus Pharmaceuticals Inc
NASDAQ:SUPN

Watchlist Manager
Supernus Pharmaceuticals Inc Logo
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Watchlist
Price: 36.18 USD -4.21% Market Closed
Market Cap: 2B USD
Have any thoughts about
Supernus Pharmaceuticals Inc?
Write Note

Supernus Pharmaceuticals Inc
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Supernus Pharmaceuticals Inc
Accrued Liabilities Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Accrued Liabilities Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Accrued Liabilities
$238.5m
CAGR 3-Years
7%
CAGR 5-Years
11%
CAGR 10-Years
28%
Johnson & Johnson
NYSE:JNJ
Accrued Liabilities
$33.5B
CAGR 3-Years
4%
CAGR 5-Years
8%
CAGR 10-Years
10%
Bristol-Myers Squibb Co
NYSE:BMY
Accrued Liabilities
$13.3B
CAGR 3-Years
10%
CAGR 5-Years
16%
CAGR 10-Years
15%
Pfizer Inc
NYSE:PFE
Accrued Liabilities
$2.6B
CAGR 3-Years
0%
CAGR 5-Years
-1%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
Accrued Liabilities
$15.7B
CAGR 3-Years
3%
CAGR 5-Years
6%
CAGR 10-Years
5%
Eli Lilly and Co
NYSE:LLY
Accrued Liabilities
$14.1B
CAGR 3-Years
21%
CAGR 5-Years
19%
CAGR 10-Years
18%

See Also

What is Supernus Pharmaceuticals Inc's Accrued Liabilities?
Accrued Liabilities
238.5m USD

Based on the financial report for Sep 30, 2024, Supernus Pharmaceuticals Inc's Accrued Liabilities amounts to 238.5m USD.

What is Supernus Pharmaceuticals Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
28%

Over the last year, the Accrued Liabilities growth was 2%. The average annual Accrued Liabilities growth rates for Supernus Pharmaceuticals Inc have been 7% over the past three years , 11% over the past five years , and 28% over the past ten years .

Back to Top